<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509804</url>
  </required_header>
  <id_info>
    <org_study_id>GeneNKT</org_study_id>
    <nct_id>NCT04509804</nct_id>
  </id_info>
  <brief_title>Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma</brief_title>
  <official_title>Target Gene Sequencing for Advanced Stage, Relapsed/Refractory Natural Killer/T-cell Lymphoma and the Correlation Between Gene Abmormalities and Chemotherapy Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although modern radiation techniques combined with chemotherapy has greatly improved the&#xD;
      local control and long-term survivals for patients with early-stage NKTCL, relapse and&#xD;
      systemic dissemination are common for localized patients. Relapsed/refractory diseases&#xD;
      together with advanced stage NKTCLs uaually progress rapidly with poor prognosis (5-year&#xD;
      overall survival rate, 0-20%). According to published studies, some recurrent genetic&#xD;
      alternations have been identified in NKTCL, including oncogene/tumor suppressive gene&#xD;
      abberants, epigenetic changes, cellular signaling pathways abnormalities, cellular apoptosis&#xD;
      related genes and so forth. However, the gene profiling techniques and materials vary in&#xD;
      different studies, no consensus has been reached on the gene abnormalities of advanced, or&#xD;
      relapsed/refractory NKTCL up to now. Additionally, gene sequencing using ctDNA of peripheral&#xD;
      blood has been unexploited in NKTCL patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Concordance</measure>
    <time_frame>2 years</time_frame>
    <description>The concordance of plasma cfDNA genotyping and tumor genotyping is defined as the ratio of gene variants detected in tumor and cfDNA to variants identified in tumor</description>
  </primary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Lymphoid Neoplasm</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to recurit 30 eligile patients who are diagnosed in our hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of NKTCL with typical morphology and immunophenotype, according to the 2008&#xD;
             World Health Organization classification of lymphomas;&#xD;
&#xD;
          2. stage III/IV disease; or relapsed or refractory disease after at least one line prior&#xD;
             teratment;&#xD;
&#xD;
          3. age â‰¥ 18 years;&#xD;
&#xD;
          4. ECOG performance status 0-2;&#xD;
&#xD;
          5. at least one measurable lesion;&#xD;
&#xD;
          6. adequate hematological, hepatic, and renal functions;&#xD;
&#xD;
          7. life expectancy of more than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously untreated stage I/II disease;&#xD;
&#xD;
          2. with no adequate tumour tissue;&#xD;
&#xD;
          3. any coexisting medical problems of sufficient severity to prevent full compliance with&#xD;
             the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mei Dong</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mei Dong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

